Fig. 2.

Lenvatinib markedly inhibited GPX2 expression in HCC. (A) Unsupervised hierarchical clustering of the top ten upregulated and downregulated mRNAs expressed in the lenvatinib treated group compared with the control group. (B) qRT-PCR to detect GPX2 expression in four HCC cells. (C) qRT-PCR results showed that lenvatinib markedly suppressed GPX2 expression in Huh7 and the other three HCC cells. (D) Western blot assay demonstrated that lenvatinib could inhibit the GPX2 expression in all the four HCC cells. (E) Represent images of the resected tumors stained with GPX2 and Ki-67 in each group from the xenograft tumors. (F) The results showed that lenvatinib markedly suppressed GPX2 expression and reduced the positive stained of Ki-67 protein. Data represents the mean ± SD of the IHC score of six independent animals for each group. (Scale bars in 2E: 200 μm; inserts: 50 μm). Statistical evaluation of the data was analyzed by two-way analysis of variance (ANOVA) with Bonferroni correction (C and F). *P < 0.05; P > 0.05, ns: no significance.